PPARs and Myocardial Infarction

Int J Mol Sci. 2020 Dec 11;21(24):9436. doi: 10.3390/ijms21249436.

Abstract

Peroxisome proliferator-activated receptors (PPARs) belong to the nuclear hormone receptor family. They are ligand-activated transcription factors and exist in three different isoforms, PPARα (NR1C1), PPARβ/δ (NR1C2), and PPARγ (NR1C3). PPARs regulate a variety of functions, including glucose and lipid homeostasis, inflammation, and development. They exhibit tissue and cell type-specific expression patterns and functions. Besides the established notion of the therapeutic potential of PPAR agonists for the treatment of glucose and lipid disorders, more recent data propose specific PPAR ligands as potential therapies for cardiovascular diseases. In this review, we focus on the knowledge of PPAR function in myocardial infarction, a severe pathological condition for which therapeutic use of PPAR modulation has been suggested.

Keywords: angiogenesis; cardiomyocytes; cardiovascular disease; endothelial cells; myocardial infarction; peroxisome proliferator-activated receptor.

Publication types

  • Review

MeSH terms

  • Animals
  • Cardiovascular Diseases / genetics
  • Cardiovascular Diseases / metabolism*
  • Humans
  • Myocardial Infarction / genetics
  • Myocardial Infarction / metabolism*
  • Myocytes, Cardiac / metabolism
  • Peroxisome Proliferator-Activated Receptors / genetics
  • Peroxisome Proliferator-Activated Receptors / metabolism*

Substances

  • Peroxisome Proliferator-Activated Receptors